» Articles » PMID: 32533097

The BLIMP1-EZH2 Nexus in a Non-Hodgkin Lymphoma

Abstract

Waldenström's macroglobulinemia (WM) is a non-Hodgkin lymphoma, resulting in antibody-secreting lymphoplasmacytic cells in the bone marrow and pathologies resulting from high levels of monoclonal immunoglobulin M (IgM) in the blood. Despite the key role for BLIMP1 in plasma cell maturation and antibody secretion, its potential effect on WM cell biology has not yet been explored. Here we provide evidence of a crucial role for BLIMP1 in the survival of cells from WM cell line models and further demonstrate that BLIMP1 is necessary for the expression of the histone methyltransferase EZH2 in both WM and multiple myeloma cell lines. The effect of BLIMP1 on EZH2 levels is post-translational, at least partially through the regulation of proteasomal targeting of EZH2. Chromatin immunoprecipitation analysis and transcriptome profiling suggest that the two factors co-operate in regulating genes involved in cancer cell immune evasion. Co-cultures of natural killer cells and cells from a WM cell line further suggest that both factors participate in immune evasion by promoting escape from natural killer cell-mediated cytotoxicity. Together, the interplay of BLIMP1 and EZH2 plays a vital role in promoting the survival of WM cell lines, suggesting a role for the two factors in Waldenström's macroglobulinaemia.

Citing Articles

Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells.

Battram A, Mane-Pujol J, Mane Pujol J, Moreno D, Oliver-Caldes A, Carpio J Blood Adv. 2024; 9(3):627-641.

PMID: 39642314 PMC: 11847098. DOI: 10.1182/bloodadvances.2024013209.


Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells.

Liu Z, Jia Y, Yang C, Liu H, Shen H, Wang H Int J Mol Sci. 2023; 24(10).

PMID: 37239949 PMC: 10218613. DOI: 10.3390/ijms24108603.


Conserved and Unique Functions of Blimp1 in Immune Cells.

Nadeau S, Martins G Front Immunol. 2022; 12:805260.

PMID: 35154079 PMC: 8829541. DOI: 10.3389/fimmu.2021.805260.


CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.

Lewis R, Maurer H, Singh N, Gonzalez-Menendez I, Wirth M, Schick M Leukemia. 2021; 35(10):2895-2905.

PMID: 34363012 PMC: 8478649. DOI: 10.1038/s41375-021-01376-1.

References
1.
Kyle R, Larson D, McPhail E, Therneau T, Dispenzieri A, Kumar S . Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clin Proc. 2018; 93(6):739-746. PMC: 5988946. DOI: 10.1016/j.mayocp.2018.02.011. View

2.
Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R . Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2011; 118(15):3793-800. DOI: 10.1002/cncr.26627. View

3.
Iwanaga M, Chiang C, Soda M, Lai M, Yang Y, Miyazaki Y . Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003. Int J Cancer. 2013; 134(1):174-80. DOI: 10.1002/ijc.28343. View

4.
Vijay A, Gertz M . Waldenström macroglobulinemia. Blood. 2007; 109(12):5096-103. DOI: 10.1182/blood-2006-11-055012. View

5.
Treon S . How I treat Waldenström macroglobulinemia. Blood. 2009; 114(12):2375-85. DOI: 10.1182/blood-2009-05-174359. View